Roberts Eiry's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Dec 8, 2023
- Accession no.
- 0001209191-23-057986
- Filed
- Dec 8, 2023
- Trade date
- Dec 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.01M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Roberts EiryCIK 0001727606 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2023 | Common Stock | MOption exerciseAcquired | +8,396 | $77.81 | +$653,292.76 | 37,917 | Direct | |
| Dec 6, 2023 | Common Stock | SSaleDisposed | −8,396 | $120.03 | −$1,007,771.88 | 29,521 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2023 | Common Stock | MOption exerciseDisposed | −8,396 | $77.81 | −$653,292.76 | 51,464 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.